<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/504BDD16-1C05-425A-B092-21D8F861A89B"><gtr:id>504BDD16-1C05-425A-B092-21D8F861A89B</gtr:id><gtr:name>St Thomas' Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5CF9155D-3F9C-4D7A-9018-14E8901E2FC6"><gtr:id>5CF9155D-3F9C-4D7A-9018-14E8901E2FC6</gtr:id><gtr:name>Belfast City Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Haematology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/504BDD16-1C05-425A-B092-21D8F861A89B"><gtr:id>504BDD16-1C05-425A-B092-21D8F861A89B</gtr:id><gtr:name>St Thomas' Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5CF9155D-3F9C-4D7A-9018-14E8901E2FC6"><gtr:id>5CF9155D-3F9C-4D7A-9018-14E8901E2FC6</gtr:id><gtr:name>Belfast City Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B89F4F15-AEDF-4A71-922C-A715F7319D43"><gtr:id>B89F4F15-AEDF-4A71-922C-A715F7319D43</gtr:id><gtr:firstName>Claire</gtr:firstName><gtr:surname>Harrison</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/950B8874-5FB9-49ED-9BEE-239200795F16"><gtr:id>950B8874-5FB9-49ED-9BEE-239200795F16</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>Green</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0300497"><gtr:id>F3F75512-602C-470D-B11D-85232FCB975A</gtr:id><gtr:title>MRC Primary Thrombocythaemia-1</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0300497</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>103608</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Thomas' Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Management and pathogenesis of myeloproliferative neoplasms</gtr:description><gtr:id>67FB281C-8D5A-477D-8EB8-9E0644F4EC05</gtr:id><gtr:impact>Please see section 1.1. In addition:
Harrison et al, ENJM 2005
Baxter et al, Lancet 2005
Campbell et al, Lancet 2005
Chen et al, Cancer Cell 2010</gtr:impact><gtr:outcomeId>M21WZweWB6p-2</gtr:outcomeId><gtr:partnerContribution>Clinical trial and laboratory researchClinical trialClinical trial</gtr:partnerContribution><gtr:piContribution>Leadership of clinical trials. Director of LLR research programme on myeloproliferative neoplasms.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Management and pathogenesis of myeloproliferative neoplasms</gtr:description><gtr:id>2AA7E242-8736-4787-BFD6-CF67D1B1D41F</gtr:id><gtr:impact>Please see section 1.1. In addition:
Harrison et al, ENJM 2005
Baxter et al, Lancet 2005
Campbell et al, Lancet 2005
Chen et al, Cancer Cell 2010</gtr:impact><gtr:outcomeId>M21WZweWB6p-1</gtr:outcomeId><gtr:partnerContribution>Clinical trial and laboratory researchClinical trialClinical trial</gtr:partnerContribution><gtr:piContribution>Leadership of clinical trials. Director of LLR research programme on myeloproliferative neoplasms.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Belfast City Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Management and pathogenesis of myeloproliferative neoplasms</gtr:description><gtr:id>EF3F8DF0-DC9A-4031-B4FA-7B00B8A58914</gtr:id><gtr:impact>Please see section 1.1. In addition:
Harrison et al, ENJM 2005
Baxter et al, Lancet 2005
Campbell et al, Lancet 2005
Chen et al, Cancer Cell 2010</gtr:impact><gtr:outcomeId>M21WZweWB6p-3</gtr:outcomeId><gtr:partnerContribution>Clinical trial and laboratory researchClinical trialClinical trial</gtr:partnerContribution><gtr:piContribution>Leadership of clinical trials. Director of LLR research programme on myeloproliferative neoplasms.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Recent advances in the myeloproliferative neoplasms</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9E09D5FE-F3E2-4908-AEEF-2111977F5B7A</gtr:id><gtr:impact>50 patients attended a talk on recent advances in the myeloproliferative neoplasms

None</gtr:impact><gtr:outcomeId>PUTPuitiQjd</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007,2009,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1632075</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KKLF grant</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>The Kay Kendall Leukaemia Fund (KKLF)</gtr:fundingOrg><gtr:id>DD7385EC-34DB-40E9-87E5-3FC7EA4BC6AD</gtr:id><gtr:outcomeId>R3pb1qCCx9o0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2300000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Specialized Center of Research/The Leukemia &amp;amp; Lymphoma Society</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>The Leukemia &amp; Lymphoma Society</gtr:fundingOrg><gtr:id>3B8AADAF-F151-418D-BD03-402EDAC0D9E2</gtr:id><gtr:outcomeId>o3mH1QDAszL0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2230206</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LRF Programme Grant</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>3C750A02-DF8A-4D65-A757-565A5C367647</gtr:id><gtr:outcomeId>nTZWRL9uSjX0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2300000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Specialized Center of Research/The Leukemia &amp;amp; Lymphoma Society, USA</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>The Leukemia &amp; Lymphoma Society</gtr:fundingOrg><gtr:id>FDE8AD69-E800-480F-9887-5F422DEDE55A</gtr:id><gtr:outcomeId>sHCWC5iomUb0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>240279</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Programme Grant</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>84B67EFC-13F8-4ACF-B01A-EFCFD600EF98</gtr:id><gtr:outcomeId>KUwbjz2QA260</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>462865</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK CTAAC</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>7C22177A-6531-40FD-AC09-A38A49A86E81</gtr:id><gtr:outcomeId>HqjjCcAoHCn0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National and International Clinical guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis</gtr:guidelineTitle><gtr:id>764B35D7-3134-4EBC-A17F-DA88FB2D6CDD</gtr:id><gtr:outcomeId>dbqDanAt2Re</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Diagnostic test and mouse model</gtr:description><gtr:id>FBE51A76-C582-4DD5-BF03-33D63EF7BCE5</gtr:id><gtr:impact>Discovery of JAK2 mutation has resulted in a new molecular classification of the myeloproliferative neoplasms. We have also generated a mouse model of the disease. We have developed several diagnostic tests (for JAK2 mutation and other mutations) which are now in routine diagnostic use in out regional diagnostic service</gtr:impact><gtr:outcomeId>kppQ5jU6h56</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Diagnostic test and mouse model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5170B2A0-A87A-424A-B6DA-514D02F1EF49</gtr:id><gtr:title>JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f38166e91e8d35a4a97e905f37b13e9"><gtr:id>2f38166e91e8d35a4a97e905f37b13e9</gtr:id><gtr:otherNames>Scott LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>WnCsP2LkUHx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFB454F1-24FC-4DC0-ACD5-20ED2D467714</gtr:id><gtr:title>Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7955f01db180d60d0a9a20c1ce54822e"><gtr:id>7955f01db180d60d0a9a20c1ce54822e</gtr:id><gtr:otherNames>Campbell PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>mmRWDXEcMH7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD614443-219D-463B-9EF4-7C6DE2A1BE6B</gtr:id><gtr:title>Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e8a2ca146c915656c5835c457bd5690"><gtr:id>7e8a2ca146c915656c5835c457bd5690</gtr:id><gtr:otherNames>Wilkins BS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>E6DV94N5uTe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9A7E875-F39C-4F92-82FA-9CFF0278A331</gtr:id><gtr:title>Independently acquired biallelic JAK2 mutations are present in a minority of patients with essential thrombocythemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/296879fed7b3e8f45170a5046d8ad06e"><gtr:id>296879fed7b3e8f45170a5046d8ad06e</gtr:id><gtr:otherNames>Beer PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>doi_53cd4cd4ca2b66c5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FA64DD5-7686-45AD-A8CC-F41128A714BB</gtr:id><gtr:title>Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba0cfae79626253c1d9a8b77df44b870"><gtr:id>ba0cfae79626253c1d9a8b77df44b870</gtr:id><gtr:otherNames>Nangalia J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>doi_53cd4cd4ca546635</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17284FF1-4008-4E5F-BEB6-C5E45EB79C26</gtr:id><gtr:title>The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/240abdc766517ea544e8186609d709b0"><gtr:id>240abdc766517ea544e8186609d709b0</gtr:id><gtr:otherNames>Jones AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>doi_53cd4cd4ca1e074a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B714304-0CC3-4522-995C-3F9D42422629</gtr:id><gtr:title>Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/296879fed7b3e8f45170a5046d8ad06e"><gtr:id>296879fed7b3e8f45170a5046d8ad06e</gtr:id><gtr:otherNames>Beer PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>jCQ5b7TLk3J</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1905C304-80E0-44B1-A7FC-E220ABD484B5</gtr:id><gtr:title>Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7955f01db180d60d0a9a20c1ce54822e"><gtr:id>7955f01db180d60d0a9a20c1ce54822e</gtr:id><gtr:otherNames>Campbell PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>TSShXH1GZdj</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0300497</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>